ASCO 2018 Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment Published: Thursday, Jun 14, ESTUDOS DE FASE I: TUCATINIBE + TRASTUZUMABE +

Slides:

Advertisements

Similar presentations

Miles D et al. Proc SABCS 2012;Abstract P

Advertisements

Dr Antonio C. Buzaid Chefe Geral Centro Avançado de Oncologia

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

1/03/09 De 89 à 98. 1/03/09 De 89 à 98 1/03/09 De 89 à 98.

Herceptin. The Scientific name is Trastuzumab and Herciptin is the Commercial name.

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Activity: #6 Case Study.  Janet Jacobson is 45 years old and went in for her routine mammogram.  The mammogram showed a questionable area in her breast.

Objectives Discuss the history of breast cancer. Describe the pathology of breast cancer and list significant tumor markers. Differentiate IHC testing.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

ESMO 2011 Breast Cancer Trastuzumab in untreated MBC Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October.

Ovarian Cancer I D ARTHUR, FRCOG. DM. March 2012.

Social Roles and Relationships.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Gerber, B; Marx, M; Untch, M; Faridi, A Breast Reconstruction Following Cancer Treatment Dtsch Arztebl Int 2015; 112(35-36): ; DOI: /arztebl

Activity: Case Study Cancer.  Janet Jacobson is 45 years old and went in for her routine mammogram.  The mammogram showed a questionable area in her.

Breast cancer facts Daniela Cazares. Fact #1 In the US, 1 in 8 women will be diagnosed with breast cancer in their lifetime.

Five Year Update of Cardiac Dysfunction in NSABP B-31 A Randomized Trial of AC  Paclitaxel vs. AC  Paclitaxel with Trastuzumab.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.

。 33 投资环境 3 开阔视野提升竞争力。 3 嘉峪关市概况。 3 。 3 嘉峪关是一座新兴的工业旅游城市，因关得名，因企设市，是长城文化与丝路文化交汇点，是全国唯一一座以长城关隘命名的城市。嘉峪关关城位于祁连山、黑山之间。 1965 年建市，下辖雄关区、镜铁区、长城区，全市总面积 2935.

Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Activity: Case Study.

Public Health Genomics 2012;15:1–10 - DOI: /

Fig. 8. Response to aromatase inhibitor and cyclin dependent kinase inhibitor in metastatic hormone receptor+, HER2 negative breast cancer. In this 29-year-old.

Perez EA et al. SABCS 2009;Abstract 80.

Figure 1. Microscopic findings and karyotyping

Having Breast Cancer Section 7.

Intention-to-treat population

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series Kevin C. Keith, Yueh Lee, Matthew G. Ewend, Timothy.

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Oncology for Family Medicine Residents:

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Electrochemotherapy in the Treatment of Massive, Multisite Breast Cancer Metastasis to the Skin and Subcutaneous Tissue: A Case Report Breast Care 2016;11:

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Neoadjuvant Therapy for HER2-Positive Breast Cancer

Tema 6. Estructura interna de la tierra.

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

Her2-positive breast cancer: updating current best practice

سرطان الثدي Breast Cancer

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Krop I et al. SABCS 2009;Abstract 5090.

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Breast Cancer Statistics

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Case Studies in Locally Advanced Pancreatic Cancer

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Having Breast Cancer Section 7.

Leto et al., Supplementary Figure S3

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

ADCC by T lymphocytes after transfection.

Comparison of ADCC by CD16V-transduced T lymphocytes and autologous NK cell. Comparison of ADCC by CD16V-transduced T lymphocytes and autologous NK cell.

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Immune Checkpoint Inhibitors in Lung Cancer

A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.

Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.

Ц.Цэнгэлмаа ХСҮТ СЗЭ-ний их эмч /АУ магистр тэргүүлэх зэрэгтэй/

Figure 1. Heterogeneous HER2 immunostaining in two gastric cancer samples classified as HER2 3+. (A) Complete ... Figure 1. Heterogeneous HER2 immunostaining.

Presentation transcript:

ASCO 2018 Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment Published: Thursday, Jun 14, ESTUDOS DE FASE I: TUCATINIBE + TRASTUZUMABE + CAPECITABINA TUCATINIBE + T-DM1